Asset
ALRIZOMADLIN
Ascentage Pharma Group International American Depository Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04275518 | phase1 | recruiting | 2020-07-06 | 2025-12-31 | Ascentage Pharma Group Inc. | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. |
| NCT04496349 | phase2 | recruiting | 2021-07-12 | 2026-05-31 | Ascentage Pharma Group Inc. | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL |
| NCT04358393 | phase1_2 | unknown | 2020-12-04 | 2024-12-30 | Ascentage Pharma Group Inc. | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS |
| NCT05701306 | phase1_2 | recruiting | 2023-02-28 | 2027-06-01 | Ascentage Pharma Group Inc. | APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors |
| NCT04785196 | phase1_2 | recruiting | 2021-05-26 | 2026-04-01 | Ascentage Pharma Group Inc. | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.